$BIOA

Analysts updated ratings for NA sector companies. Clear Street's Owen Lau reiterated a Buy rating on Fair Isaac (FICO) with a $1600 price target. Freeport-McMoRan (FCX) was kept at Hold by Bernstein's Bob Brackett. BioAge Labs (BIOA) received a Buy rating from Needham's Joseph Stringer with a $35 target. Analyst consensus for FICO is Moderate Buy, FCX is Strong Buy, and BIOA is Strong Buy.

Cormorant Asset Management, LP and Bihua Chen filed an amended Schedule 13G reporting beneficial ownership of 2,390,605 shares of BioAge Labs, Inc. common stock, or 5.38% of the class. The filing states the shares carry shared voting and dispositive power, and the percentage is based on 44,452,734 shares outstanding as of May 1, 2026.

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in th

BioAge Labs (BIOA) and Monte Rosa Therapeutics (GLUE) fell after Novo Nordisk (NVO) reported its late-stage ZEUS trial for ziltivekimab failed to reduce heart attack, stroke, and related deaths despite lowering inflammation markers. BIOA dropped 64% and GLUE about 27%. Analysts cut BIOA and GLUE price targets while keeping Buy ratings.

BioAge Labs shares dropped about 59.6% after Novo Nordisk reported its Phase 3 ZEUS trial of ziltivekimab failed to reduce major adverse cardiovascular events versus placebo in 6,300+ patients, with a hazard ratio of 0.99. The result challenged the cardiovascular inflammation approach relevant to BioAge’s BGE-102 (QUELL-CV Phase 2).

RTTNews reports notable premarket moves ahead of Friday’s open, highlighting gainers including REPL (+131% to $12.49), AXT (+34% to $62.94), COHU (+24% to $57.70) and NWL (+19% to $6.11). Losers include BIOA (-53% to $11.64), DFNS (-49% to $43.50), GLUE (-29% to $16.00) and PN (-27% to $17.20).

BioArctic AB said its partner Eisai reported preliminary Q2 2026 global Leqembi sales of JPY 29.3 billion. BioArctic’s royalty is SEK 179 million, about 10% higher than in Q2 2025. Excluding a Q2 2025 China stockpiling effect of about JPY 5.3 billion, royalty revenues rose about 43% year over year. BioArctic’s Q2 report is due Aug 26, 2026.

HitGen Inc. (SSE:688222) said its partner BioAge Labs (NASDAQ:BIOA) dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102, an oral NLRP3 inhibitor for cardiovascular risk reduction. BioAge expects topline Phase 2 data in H2 2026. Phase 1 reportedly showed hsCRP reductions on once-daily dosing.

BioArctic AB said Eisai received FDA approval for a supplemental BLA allowing once-weekly subcutaneous lecanemab-irmb (Leqembi Iqlik) as a starting dose for early Alzheimer’s. The regimen is 500 mg weekly (two 250 mg injections). US launch is planned for late Aug 2026. Patients can use SC or IV throughout treatment.

Barton Shane (Principal Accounting Officer) sold 62,566 shares of BioAge Labs, Inc. (BIOA) at an average of $25.20 ($25.19–$25.21, $1.58M total) across 2 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.